论文部分内容阅读
目的探究苦参素联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效,并分析其作用机制。方法 75例乙型肝炎肝硬化患者,随机分为对照组37例,观察组38例。对照组采用临床上常规用药恩替卡韦对患者进行治疗;观察组在对照组基础上加苦参素治疗。记录两组患者治疗前后体内的肝纤维化情况,并对记录结果进行统计学的处理分析。结果两组患者经治疗后,体内的肝纤维化程度都有大幅度下降,且治疗结束后,观察组的肝纤维化的水平明显要小于对照组,差异具有统计学意义(P<0.05)。结论采用苦参素联合恩替卡韦来治疗乙型肝炎肝硬化,能有效缓解乙型肝炎肝硬化情况,降低患者体内肝纤维程度,临床疗效显著,应当引起广大医学卫生工作者的重视。
Objective To investigate the clinical efficacy of oxymatrine combined with entecavir in the treatment of hepatitis B cirrhosis and to analyze its mechanism of action. Methods Seventy-five patients with hepatitis B cirrhosis were randomly divided into control group (n = 37) and observation group (n = 38). The control group was treated with entecavir in clinical routine. The observation group was treated with matrine on the basis of the control group. The liver fibrosis in both groups before and after treatment was recorded, and the results of the treatment were statistically analyzed. Results After treatment, the degree of hepatic fibrosis in both groups decreased significantly. After the treatment, the level of hepatic fibrosis in the observation group was significantly less than that in the control group (P <0.05). Conclusion The use of oxymatrine combined with entecavir in the treatment of hepatitis B cirrhosis can effectively relieve the cirrhosis of hepatitis B and reduce the degree of liver fibrosis in patients with clinically significant effect, which should arouse the attention of the majority of medical and health workers.